- Report
- October 2025
- 190 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 193 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- August 2025
- 188 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- August 2025
- 197 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- August 2025
- 198 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- August 2025
- 197 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 186 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 194 Pages
Global
From €3157EUR$3,545USD£2,755GBP
€3508EUR$3,939USD£3,061GBP
- Report
- October 2025
- 278 Pages
Global
From €5210EUR$5,850USD£4,547GBP
- Report
- October 2025
- 369 Pages
Global
From €5210EUR$5,850USD£4,547GBP
- Report
- October 2025
- 285 Pages
Global
From €5210EUR$5,850USD£4,547GBP
- Report
- October 2025
- 281 Pages
Global
From €5210EUR$5,850USD£4,547GBP
- Report
- October 2025
- 391 Pages
Global
From €5210EUR$5,850USD£4,547GBP
- Clinical Trials
- July 2025
- 60 Pages
Global
From €1069EUR$1,200USD£933GBP
€1336EUR$1,500USD£1,166GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1425EUR$1,600USD£1,244GBP
€1781EUR$2,000USD£1,554GBP
- Drug Pipelines
- April 2025
- 100 Pages
Global
From €1425EUR$1,600USD£1,244GBP
€1781EUR$2,000USD£1,554GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1069EUR$1,200USD£933GBP
€1336EUR$1,500USD£1,166GBP
- Drug Pipelines
- April 2025
- 70 Pages
Global
From €1069EUR$1,200USD£933GBP
€1336EUR$1,500USD£1,166GBP
- Drug Pipelines
- April 2025
- 50 Pages
Global
From €1069EUR$1,200USD£933GBP
€1336EUR$1,500USD£1,166GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1069EUR$1,200USD£933GBP
€1336EUR$1,500USD£1,166GBP

The Antimicrobial Resistance (AMR) market is a subset of the healthcare services industry that focuses on the development of treatments and strategies to combat the growing threat of drug-resistant bacteria. AMR is a major public health concern, as it can lead to increased morbidity and mortality, as well as higher healthcare costs. To address this issue, the market is focused on developing new antibiotics, diagnostics, and vaccines, as well as strategies to reduce the spread of drug-resistant bacteria. Additionally, the market is focused on improving the stewardship of existing antibiotics, as well as developing new strategies to reduce the emergence of drug-resistant bacteria.
Some companies in the AMR market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson, Novartis, and AstraZeneca. Show Less Read more